Determination of appropriate breast cancer treatments and prognostic outcomes are dependent on the accurate histologic classification and measurement of two main biomarker groups: hormone receptors (HRs; including oestrogen (ER) and progesterone receptors (PR)) and human epidermal growth factor 2 (HER2) [1]. This evidence concerns the gene PGR and breast carcinoma.